Hikal Ltd. (BSE: 524735) is a Navi Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹2,758 Cr, it ranks #1,090 by market cap among the 6,197 Indian listed companies on FinBizNet, and #34 of 86 in Medicinal Chemicals and Botanical Products. At ₹223.65 (as of 16 Nov 2026), the share price is 14.3% below its 52-week high of ₹261.00 and 52.9% above its 52-week low of ₹146.25. The share price is down 5.6% over one year and up 2.8% over three months.
| Current Price | ₹223.65 |
|---|---|
| Market Cap | ₹2,758 Cr |
| BSE Code | 524735 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -3.97% |
| Return on Assets | 1.45% |
| 52-Week Range | ₹146.25 – ₹261.00 |
| 1-Year Price Change | -5.6% |
| 3-Month Price Change | +2.8% |
| Beta (1Y) | 0.88 |
| Dividend Yield | 0.36% |
| Headquarters | Navi Mumbai, Maharashtra |
| Website | www.hikal.com |
| Revenue | ₹434 Cr |
|---|---|
| Net Profit | ₹-6 Cr |
| Net Margin | -1.4% |
| EPS (Basic) | ₹-0.49 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Hikal Ltd. reported revenue of ₹434 Cr in Q2 FY27, up 36.3% from ₹319 Cr in Q2 FY26 and up 7.8% from ₹403 Cr in Q1 FY27. It posted a net loss of ₹6 Cr for the quarter, against a net loss of ₹35 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹319 Cr (Q2 FY26) to ₹552 Cr (Q4 FY25). The company reported a net loss in 5 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹434 Cr | −₹6 Cr | −1.4% |
| Q1 FY27 | ₹403 Cr | −₹7 Cr | −1.8% |
| Q4 FY26 | ₹519 Cr | ₹14 Cr | 2.8% |
| Q3 FY26 | ₹494 Cr | −₹6 Cr | −1.2% |
| Q2 FY26 | ₹319 Cr | −₹35 Cr | −11.0% |
| Q1 FY26 | ₹380 Cr | −₹22 Cr | −5.9% |
| Q4 FY25 | ₹552 Cr | ₹50 Cr | 9.1% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 68.85% of Hikal Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 37.8% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as
1. Crop Protection Products-This segment manufactures pesticides and herbicides. It is also involved in custom synthesis and custom manufacturing of intermediates and active ingredients. 2. Pharmaceuticals-This segment produces in active pharmaceutical ingredients. It is also involved in contract research activities. 3. Corporate / Unallocated Segment-0 4. Pharmaceuticals - Overseas Operation-This segment manufactures and supplies active pharmaceutical ingredients in India. It also engages in the contract research, custom synthesis, and custom manufacture of active pharmaceutical ingredients.
1. Pharmaceuticals-59.6% 2. Crop Protection-40.4%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Hikal Ltd. | ₹2,758 Cr | n/m | -3.97% | ₹434 Cr | -5.6% |
Listed by market capitalisation. Ratios are shown for context only.
Hikal Ltd. is trading at ₹223.65, with a market capitalisation of ₹2,758 Cr.
Hikal Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Hikal Ltd. has a return on equity of -3.97%.
Hikal Ltd. is listed on the BSE under the scrip code 524735.
Hikal Ltd.'s share price is down 5.6% over one year and up 2.8% over three months. Its 52-week range is ₹146.25 to ₹261.00.
In Q2 FY27, Hikal Ltd. reported revenue of ₹434 Cr and net profit of ₹-6 Cr, with basic EPS of ₹-0.49 (consolidated, parsed from the company's exchange filing).
Hikal Ltd. reported revenue of ₹434 Cr in Q2 FY27, up 36.3% from ₹319 Cr in Q2 FY26 and up 7.8% from ₹403 Cr in Q1 FY27.
Promoters held 68.85% of Hikal Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.